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Tumor suppressor genef the major responses to stress in eukaryotic cells, and is regulated by a complex
network of signaling cascades. Not surprisingly, autophagy is implicated in multiple pathological processes,
including infection by pathogens, inﬂammatory bowel disease, neurodegeneration and cancer. Both
oncogenesis and tumor survival are inﬂuenced by perturbations of the molecular machinery that controls
autophagy. Numerous oncoproteins, including phosphatidylinositol 3-kinase, Akt1 and anti-apoptotic
members of the Bcl-2 family suppress autophagy. Conversely, several tumor suppressor proteins (e.g.,
Atg4c; beclin 1; Bif-1; BH3-only proteins; death-associated protein kinase 1; LKB1/STK11; PTEN; UVRAG)
promote the autophagic pathway. This does not entirely apply to p53, one of the most important tumor
suppressor proteins, which regulates autophagy in an ambiguous fashion, depending on its subcellular
localization. Irrespective of the controversial role of p53, basal levels of autophagy appear to inhibit tumor
development. On the contrary, chemotherapy- and metabolic stress-induced activation of the autophagic
pathway reportedly contribute to the survival of formed tumors, thereby favoring resistance. In this context,
autophagy inhibition would represent a major therapeutic target for chemosensitization. Here, we will
review the current knowledge on the dual role of autophagy as an anti- and pro-tumor mechanism.
© 2009 Elsevier B.V. All rights reserved.1. Introduction“Autophagy” is a term of Greek derivation that indicates several
intracellular pathways converging on a common phase of lysosomal
degradation, including chaperone-mediated autophagy, micro- and
macroautophagy. During macroautophagy (to which we refer as
“autophagy”), intact organelles and/or parts of the cytoplasm are
enclosed in double-membraned vacuoles that are known as
autophagosomes. Autophagosomes (formerly also termed “earlyatg, autophagy related; Bec-1,
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ll rights reserved.autophagic vacuoles”) mature by fusing with lysosomes, thereby
forming the so-called autophagolysosomes/autolysosomes (formerly
dubbed “late autophagic vacuoles”), in which lysosomal hydrolases
are activated and degrade the luminal content [1]. Usually, the
cytoplasmic accumulation of autophagosomes (which can be
observed by electron microscopy) coincide with an upregulation of
the autophagic pathway. Nonetheless, autophagolysosomes can also
amass when lysosomal degradation is inhibited, for instance upon
small interfering RNA (siRNA)-mediated downregulation of the
lysosome-associated membrane protein 2 (LAMP-2) or in the
presence of hydroxychloroquine [2]. Thus, at least another parameter
(such as the cleavage and/or the redistribution of the autophago-
some marker LC3 or the destruction of the autophagic substrate p65)
should be monitored to quantify autophagic ﬂow in an unambiguous
fashion [3,4].
Autophagic vacuolization has been observed in numerous patho-
physiological scenarios [5,6], and the term “autophagic cell death” has
been extensively employed to indicate a cell death subroutine lacking
themorphological features of classical apoptosis and rathermanifesting
with the cytoplasmic accumulation of autophagosomes [7]. In the vast
majority of these settings, however, pharmacological and/or genetic
inhibition of autophagy does not prevent cell death, and often
accelerates it. Thus, autophagy is presumably activated by dying cells
as part of an (inconclusive) attempt to cope with stress, yet mainly
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expression “autophagic cell death” has been recently recognized as a
misnomer, and theNomenclature CommitteeonCell Deathhas strongly
discouraged its use in scientiﬁc reports [9,10].
Baseline levels of autophagy contribute to the physiological
elimination of old/damaged organelles as well as to the turnover of
long-lived proteins. Moreover, the autophagic ﬂow can be dramatically
augmented in response to numerous conditions of extracellular and/or
intracellular stress [8,11]. Among others, these include nutrient and/or
growth factor deprivation, hypoxia, proteinmisfolding and infection by
intracellular pathogens. In starvation conditions, enhanced autophagy
provides the cells with metabolic intermediates to meet their
bioenergetic demands [12]. During hypoxia, the selective removal of
reactive oxygen species (ROS)-overproducing mitochondria through
the autophagic pathway (a process known as mitophagy) may limit
oxidative damage [13]. The autophagic elimination of protein aggre-
gates contributes to the cytoprotective mechanism known as unfolded
protein response (UPR) [14], inwhich the endoplasmic reticulum plays
a prominent role [15,16]. Finally, upon invasion, autophagy favors the
clearance of intracellular pathogens, thereby representing the most
ancient effector mechanism of innate immunity [17].
These few examples substantiate the notion that autophagy
occupies a central position in the response of eukaryotic cells to
intrinsic and environmental stress. Intriguingly, several genetic and
epigenetic modiﬁcations that have been associated with oncogenesis
(including activation and/or ampliﬁcation of oncoproteins and
mutation/inactivation of tumor suppressor proteins) also negatively
regulate the cellular machinery for autophagy, which suggests that
basal levels of autophagy may function as a tumor suppressor
mechanism [18]. Conversely, multiple lines of evidence indicate that
autophagy may contribute to the survival of established tumors, for
instance by allowing adaptation to adverse metabolic conditions or by
favoring chemoresistance [18]. In this review, we will discuss the
molecular mechanisms underlying the anti-tumor and pro-tumor
roles of autophagy.
2. Anti-tumor roles of autophagy in oncogenesis
Themammalian target of rapamycin (mTOR) kinase represents the
major negative regulator of autophagy in human cells. In all higher
eukaryotes, mTOR is part of at least two distinct multiprotein
complexes (known as TOR complexes, TORCs, or CREB-regulated
transcription coactivators, CRTCs), which exhibit partially overlapping
functional proﬁles. In physiological conditions, mTOR prevents
autophagy by maintaining the hyperphosphorylation of proteins
required for the initiation of the autophagic cascade. Conversely,
mTOR activity is rapidly shut down in conditions of stress, which
allows for the rapid upregulation of autophagy [8]. mTOR takes part in
multiple signaling cascades that regulate cell growth, and especially in
those emanating from receptor tyrosine kinases (RTKs). In cancer
cells, constitutively active RTKs and/or the persistent production of
autocrine growth factors lead to the hyperphosphorylation of mTOR
substrates. Moreover, several tumors are characterized by activating
mutations of the key signal transducers connecting RTKs to mTOR,
including the small GTPase Ras, phosphatidylinositol 3-kinase (PI3K)
as well as the kinases Akt1 and 3-phosphoinositide dependent protein
kinase 1 (PDPK1) [19,20]. Finally, mTOR function can be augmented in
tumor cells as a result of mutations that inactivate negative regulators
of the RTK–mTOR signaling axis [20]. These include neuroﬁbromin 1
(NF1, an antagonist of Ras), tuberous sclerosis complex 1 and 2 (TSC1
and 2, which form a functional complex inhibiting mTOR-mediated
phosphorylation of translation regulators) [21], LKB1/STK11 (a kinase
that positively regulates the AMP-activated protein kinase, AMPK, and
hence TSC2) [22,23], as well as the Ras-related protein ARHI/DIRAS3
[24] and the phosphatase PTEN (both of which function as direct
antagonists of PI3K) [19]. Interestingly, germline mutations of thenearly all these proteins have been associated with familial cancer
syndromes (e.g., neuroﬁbromatosis type 1, tuberous sclerosis, Peutz–
Jegher's syndrome, Cowden's disease), which share clinical features
characterized by hamartomatous tumors [20]. In line with these
observations, it has been demonstrated that constitutively active Akt1
functions as an autophagy inhibitor in vitro and in vivo, while
promoting tumor growth in vivo, in particular in cells that fail to
express the pro-apoptotic proteins Bax and Bak (Table 1) [25].
Reduced levels (or the complete absence) of multiple proteins that
are required for autophagy have also been associated with facilitated
tumor progression, both in animal models and in humans (Table 1).
The essential autophagy regulator beclin 1 (Bec-1, the human ortholog
of murine Atg6) interacts with several cofactors (including Ambra1,
Bif-1 and UVRAG) to activate the lipid kinase Vps34, which is required
for the initiation of autophagic pathway [26–28]. Immortalized kidney
and mammary epithelial cells that harbor a monoallelic deletion of
bec-1 are characterized by increased growth rates – as compared to
their wild type (WT) counterparts – upon the inoculation into
immunodeﬁcient recipient mice [25,29,30]. atg6+/− heterozygous
mice display an increased propensity to develop age-related tumors
(including mammary precancerous lesions, lymphomas as well as
lung and hepatocellular carcinomas), and are more susceptible to
hepatitis B virus-induced carcinogenesis than their WT littermates
[31,32]. One copy of the bec-1 gene is deleted in a relevant fraction of
human breast, ovarian and prostate tumors [33]. Moreover, a large
proportion of brain cancers are characterized by reduced levels of Bec-1
protein, which inversely correlate with clinical malignancy [34].
Altogether, these observations point to Bec-1 as a bona ﬁde tumor
suppressor protein [32], a property that might be shared with other
components of the Bec-1-containing Vps34-activating complex. One
copy of the uvrag gene is often deleted in human colon cancers, and
UVRAG overexpression has been shown to suppress the tumorigenicity
of human colon cancer cells [27]. Moreover, bif-1−/− mice sponta-
neously develop lymphomas, sarcomas and carcinomas at higher
frequency than WT animals [28]. Since the ambra1 gene knockout
results in profound neurological defects and early embryonic lethality
[26], data on the propensity of ambra1−/− mice to develop sponta-
neous tumors are lacking.However, someof theproteins that constitute
themolecularmachinery for autophagy downstreamof Bec-1 have also
been associated with tumor suppressing functions. As an example, in
mice, the biallelic deletion of atg4C (which codes for a cysteine protease
involved in the processing of LC3/Atg8) results in tissue-speciﬁc
defects of the autophagic pathway, and favors the development of
chemically-induced ﬁbrosarcomas [35].
Bec-1 has been ﬁrst identiﬁed as a Bcl-2-interacting protein [33].
Bcl-2 and its anti-apoptotic homologues (e.g., Bcl-XL, Bcl-w andMcl-1)
are prominent oncoproteins [36], while their pro-apoptotic counter-
parts (e.g., Bax, Bak and BH3-only proteins) exert tumor suppressing
roles [37–39]. Whereas the implication of the Bcl-2 protein family in
tumorigenesis was initially ascribed only to their ability to modulate
cell death, it has now become evident that these factors control
multiple aspects of metabolism, including autophagy (Table 1) [40]. In
particular, anti-apoptotic factors like Bcl-2 [41], Bcl-XL [42], Bcl-w [43]
and Mcl-1 [42] suppress autophagy, mainly by interacting with and
therefore inhibiting Bec-1. Accordingly, inhibition of Bcl-2 by RNA
interference (RNAi) [44] or via speciﬁc antisense oligonucleotides [45]
has been shown to induce autophagy in multiple tumor cell lines.
Conversely, pro-apoptotic BH3-only proteins including Bad [42], Bik
[46], BNIP3L [47,48], Noxa, Puma and BimEL [49] promote the
autophagic ﬂow, (at least in part) by freeing Bec-1 from inhibitory
interactions with anti-apoptotic Bcl-2-like proteins. Such interactions
involve the BH3 domain of Bec-1 [50] and the so-called “BH3 receptor”
domain of anti-apoptotic Bcl-2 family members, and can be disrupted
by small BH3-mimetic chemicals like ABT-737 [42,51]. In apoptosis-
resistant cells, ABT-737 efﬁciently disrupts Bec-1/Bcl-2 and Bec-1/Bcl-
XL complexes, thereby inducing massive autophagy [52]. This effect
Table 1
Examples of autophagy regulation by oncoproteins and tumor suppressor proteins.
Name Link(s) to tumorigenesis Link(s) to autophagy Ref.
Oncogenes
Akt1 Gain-of-function mutations or ampliﬁcations found in a
high fraction of human cancers
Constitutively active Akt1functions as an autophagy
inhibitor in vitro and in vivo
[20]
ARHI/DIRAS3 Downregulated in more than 60% of ovarian cancers Induces autophagy by blocking PI3K signaling, thereby
inhibiting mTOR. Upregulates Atg4C Colocalizes with
cleaved LC3 in autophagosomes
[24]
Bcl-2 Bcl-XL Overexpressed in a relevant proportion of human cancers,
and notably in hematological malignancies
Negatively regulate autophagy by sequestering Bec-1 [40,111]
LKB1/STK11 Germline mutations cause Peutz-Jecgher's syndrome.
Somatic mutations observed in NSCLC.
Activates AMPK and hence TSC2 May also stimulate
autophagy by stabilizing p27KIP1
[22,23]
NF1 Loss-of-function mutations cause type I neuroﬁbromatosis Ras antagonist, negatively regulates the RTK–mTOR
pathway
[20]
PDPK1 Gain-of-function or ampliﬁcations of PDPK1 characterize
several human tumors
Positive signal transducer of the RTK–mTOR pathway [20]
PI3K Gain-of-function mutations or ampliﬁcations of PI3K are
common to many human cancers
mTOR activating kinase [19]
PTEN Germline mutations cause Cowden's disease. Mutated or
silenced in several tumors
Phosphatase that antagonizes the activity of PI3K, thereby
inhibiting mTOR
[19,20]
Ras Hyperactivated in most human cancers Signal transducer of the RTK–mTOR pathway [20]
TSC-1 TSC-2 Germline mutations cause tuberous sclerosis TSC-1 and -2 form a functional complex inhibiting mTOR-
mediated phosphorylation
[21]
Oncosuppressors
Atg4c Implicated in the development of chemically-induced
ﬁbrosarcomas
Cysteine protease required for a proper autophagic
response under stressful conditions
[35]
Bec-1 Deleted in a relevant fraction of human breast, ovarian and
prostate tumors. Brain tumors are characterized by
reduced expression of Bec-1
Essential modulator of autophagy [33,65]
BH3-only proteins Loss of expression due to inactivating mutations has been
recorded in multiple human tumors (e.g., melanoma, renal
cell carcinoma)
BH3-only proteins promote autophagy by freeing Bec-1
from inhibitory interactions with anti-apoptotic members
of the Bcl-2 protein family
[42,46–49]
Bif-1 Knockout of bif-1 signiﬁcantly enhances the development
of spontaneous tumors in mice
Interacts with Bec-1 through UVRAG and functions as a
positive regulator of the class III PI3K
[28]
DAPK-1 Frequently silenced in human tumors by epigenetic
mechanisms
Induces autophagy by interaction with the microtubule-
associated factor MAP1B. May promote autophagy via
activation of p53
[54]
p14ARF Mutated or lost in multiple types of human cancer
including leukemia, lymphoma, breast carcinoma and
NSCLC
Full length p14ARF promotes autophagy by interacting with
MDM2, thereby de-inhibiting the transcriptional functions
of p53
[61]
p150 (?) Overexpressed in a large fraction of gastric and esophageal
carcinomas. Expression inversely correlates with clinical
grade
Favors autophagy by interacting with Bec-1 and hVps34,
forming a functional PI3K complex
[63,64]
p53 Mutated inN50% of all human tumors Nuclear p53 transactivates autophagy-promoting factors
(e.g., DAPK-1, DRAM). Cytoplasmic p53 exerts a tonic
inhibition of autophagy
[69,84]
Rab7 Rearranged in several types of leukemia Participates in the maturation of autophagosomes [65,67]
smARF Mutated or lost in multiple types of human cancer
including leukemia, lymphoma, breast carcinoma and
NSCLC
Promotes autophagy independently of p53, presumably by
releasing Bec-1 by Bcl-XL-mediated inhibition
[58–60]
UVRAG Monoallelically deleted at high frequency in human colon
cancers
Interacts with Bec-1 to form a class III PI3K signaling
complex
[65]
Abbreviations: AMP-activated protein kinase; atg, autophagy related; Bec-1, beclin 1; BH3, Bcl-2 homology domain 3; DAPK-1, death-associated protein kinase 1; DRAM, damage-
regulated autophagy modulator; NF1, neuroﬁbromin 1; mTOR, mammalian target of rapamycin; NSCLC, non-small cell lung cancer; PDPK1, 3-phosphoinositide dependent protein
kinase 1; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine kinase; STK11, serine threonine kinase 11; TSC, tuberous sclerosis;
UVRAG, UV radiation resistance associated gene.
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be efﬁciently prevented by transfectionwith aMcl-1-encoding plasmid
or by small interfering RNAs (siRNAs) targeting Bec-1, in line with the
notions that ABT-737 fails to occupy the BH3 receptor domain of Mcl-1
[51] and that its pro-autophagic effects depend on Bec-1 [52]. The fact
that oncoproteins and tumor suppressors proteins from theBcl-2 family
also control autophagy further substantiates the notion that tumor
development may be favored by autophagy inhibition.
Additional lines of evidence corroborate this idea (Table 1). For
instance, the expression of the death-associated protein kinase 1
(DAPK-1) is commonly shut down in human tumors by epigenetic
mechanisms [53]. Similarly to BH3-only proteins, DAPK-1 can induce
apoptosis and autophagy by independent mechanisms, thereby
displaying pronounced tumor and metastasis suppressing functions.
On one hand, DAPK-1 contributes to cell death by catalyzing thephosphorylation of myosin light chain, which mediates apoptotic
membrane blebbing [54]. On the other hand, DAPK-1 promotes
autophagy by binding to the microtubule-associated protein MAP1B
[54], which is an LC3 interactor with anti-autophagic functions [55].
Since DAPK-1 exerts a wide range of functions and can also activate
the p53 system (which represents one of the most prominent tumor
suppressor mechanisms in humans, see below) [53], it remains
formally possible that DAPK-1-activated transcriptional programs
might also stimulate autophagy.
The expression of another positive regulator of p53, p14ARF, is lost in
a large number of human tumors (including lung carcinoma,
melanoma and prostate cancer), due either to inactivating mutations
or heterochromatinization-dependent gene repression [56]. In the
nucleolus, p14ARF binds to the product of the mdm2 gene, thereby
preventing the ubiquitination-dependent destruction of p53 [57]. A
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massive autophagy independently of p53 [58], possibly by interacting
with Bcl-XL, thereby freeing Bec-1 [59]. Thus, the tumor suppressing
functions of smARF may not be limited to its pro-apoptotic potential.
Only upon extreme overexpression, full length p14ARF localizes to
nuclear and extranuclear compartments, therebyactivating autophagy
via both p53-dependent and p53-independent mechanisms [60,61].
Conversely, nucleolus-restricted expression p14ARF fails to induce
autophagy when p53 is inactive [60], indicating that the pro-
autophagic action of p14ARF from within the nucleolus completely
relies on p53-dependent transcriptional programs.
p150 positively regulates autophagy by interacting with Bec-1 and
hVps34, thereby forming a functional PI3K complex [62], and its
expression is augmented in a large fraction of gastric and esophageal
carcinomas [63,64]. These apparently counterintuitive data may point
to an autophagy-unrelated function of p150 that may be important for
the development of gastric/esophageal cancers. Nonetheless, it
should be noted that high p150 expression characterized most low-
grade lesions, and that p150 was progressively lost in invasive and
metastatic tumors [63].
In mammalian cells, the small GTPase Rab7 also participates in the
PI3K-dependentmaturation of autophagic vacuoles [65]. Interestingly,
the rab7 gene maps to a locus of chromosome 3 that is frequently
rearranged in different types of leukemia [66]. Moreover, Rab7 can
limit growth-factor independent survival by preventing the cell-
autonomous expression of nutrient transporters [67].
Taken together, these observations strongly support the idea that
autophagy inhibition favors tumorigenesis, in turn suggesting that
autophagy may represent a bona ﬁde tumor suppressor mechanism
(Fig. 1). At least three hypotheses can be put forward to explain how
reduced autophagymay stimulate tumorigenesis [68]. First, autophagy
inhibition reportedly augments necrotic cell death within tumors, and
may therefore promote tumor growth by aggravating local inﬂamma-Fig.1. Tumor suppressing functions of autophagy. In 2000, Hanahan andWeinberg [108] enum
growth signals, insensitivity to antiproliferative signals, unlimited replicative potential, pro
Subsequently, escape from immune surveillance and enhanced anabolism have been prop
suppressor mechanism by (at least) three distinct means, namely by preserving genome s
inﬂammation. Thus, autophagy inhibition may represent yet another hallmark of tumors.tion [25]. Second, compromised autophagy has been shown to promote
chromosomal instability, in particular in cells subjected to metabolic
stress, which may lead to oncogene activation and tumor progression
[29,30]. However, themechanisms throughwhich autophagy preserves
genome integrity remain elusive. An intriguing possibility is that
autophagy may contribute to the regulation of the cell cycle, for
instance by degrading proteins and/or organelles involved in speciﬁc
cell cycle checkpoints [69]. Alternatively, autophagymight function at a
more general level to ensure the minimal supply of ATP and other
metabolites required for DNA repair [70]. Third, deﬁcient autophagy
may promote tumorigenesis by allowing for the accumulation of old
and/or damaged organelles, which in turn may act as sources of
intrinsic genotoxic/tumorigenic chemical species (e.g., ROS from
uncoupled mitochondria) [13].
3. Controversial regulation of autophagy by p53
The general rule that tumor suppressor proteins facilitate auto-
phagy does not entirely apply to themost important tumor suppressor
protein of all, p53 (Fig. 2) [71]. The p53 system is blocked inmore than
50% of human cancers, for instance due to inactivating mutations of
p53 or of genes coding for p53-phophorylating kinases (e.g., ATM,
Chk1), following the ampliﬁcation-dependent overexpression of
MDM2, the E3 ubiquitin ligase that directs p53 to proteasome-
mediated degradation, or as a result of the loss of p14ARF function
[72,73]. p53 was initially described as a transcription factor that
transactivates pro-apoptotic and cell cycle arresting programs [72],
therefore inducing apoptosis and/or senescence of cancer cells
characterized by irreparable genomic alterations, either in the context
of tumor progression or following chemo- and/or radiotherapy [73].
Moreover, p53 is able to transactivate the gene coding for the
lysosomal protein damage-regulated autophagy modulator (DRAM),
which can trigger autophagy but is also required for p53-mediatederated six cell-intrinsic hallmarks of cancer, and in particular: provision of autonomous
duction of angiogenic factors, disabled apoptosis and tissue invasion with metastasis.
osed as additional features that characterize cancer cells. Autophagy acts as a tumor
tability, by limiting oxidative stress, and by reducing intratumoral necrosis-dependent
Fig. 2. The p53 network and autophagy. The p53 system can be activated byDNAdamage
and other stress signals through the p14ARF-dependent sequestration of MDM2, the E3
ubiquitin ligase that normally targets p53 to proteasomal degradation. In the nucleus,
active p53 tetramers bind DNA and can transactivate pro-apoptotic (e.g., Bax, BH3-only
proteins), cell cycle-arresting (e.g., p21CIP1, Gadd45α) or autophagy-promoting (e.g.,
DAPK-1, DRAM) factors. Moreover, p53 can translocate to mitochondria and directly
promote cell death, by favoring mitochondrial membrane permeabilization (MMP).
Presumably, p53-induced MMP results from the binding of p53 to both pro- (e.g., Bax)
and anti-apoptotic (e.g., Bcl-2, Bcl-XL) members of the Bcl-2 family. Cytoplasmic p53 has
also been shown to suppress autophagy, through yet undetermined protein interactors
or via hitherto undetermined metabolic circuitries. Both full-length p14ARF and a small
mitochondrial isoform of this protein (smARF) have been shown to promote autophagy.
In particular, smARF may promote the autophagic ﬂow by releasing Bec-1 from Bcl-XL-
dependent inhibitory interactions. Endogenous levels of p14ARF result in a near-to-
complete localization within the nucleolar compartment, where the pro-autophagic
functions of p14ARF completely rely on p53. Conversely, mitochondrial smARF also
activates autophagy in p53-independent fashion.
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documented the induction of p53-dependent autophagic responses,
for instance upon DNA damage [75], ARF activation [61], or following
the reintroduction of exogenous p53 in p53−/− cancer cells [76].
Recently, great attention has been paid to the transcription-
independent functions of cytosolic p53 (Fig. 2). First, it has been
demonstrated that active p53 can accumulate in the cytosol and
initiate mitochondrial cell death [77–80], either by directly activating
Bax [81] and/or by inhibiting anti-apoptotic members of the Bcl-2
protein family [82]. In this context, the p53-dependent transactivation
of Puma (a BH3-only protein that promotes the disruption of
inhibitory complexes engaging Bax and p53 with Bcl-2/Bcl-XL)
would couple nuclear and extranuclear functions of p53 [83].
Moreover, cytosolic p53 has been shown to exert a tonic inhibition
of the autophagic ﬂow [69]. Thus, human, mouse and nematode cells
subjected to knockout, knockdown or pharmacological inhibition of
p53 manifest several signs of enhanced autophagy, including LC3
maturation/redistribution and appearance of autophagic vacuoles
[4], both in vitro and in vivo [69]. p53 inhibition also promotes
autophagy in enucleated cells, suggesting that the nuclear pool of p53
is not directly implicated in the suppression of autophagy [69]. In line
with this notion, upon reintroduction in p53−/− human colon cancer
cells, several cancer-associated p53 mutants were shown to inhibit
autophagy to an extent that correlated with their propensity to
redistribute to the cytoplasm [84]. In particular, maximal autophagy
inhibition was observed upon the expression of a p53 mutant that is
actively excluded from the nuclear compartment due to the deletion
of its nuclear localization sequence. On the contrary, deletion of the
nuclear export signal (which results in the accumulation of p53
within the nucleus) totally abolished p53 autophagy-inhibitory
functions [69,84].Intriguingly, large deletions affecting the DNA-binding domain of
p53 had no effects on the suppression of autophagy by cytoplasmic
p53 [84]. Some amino acids of the DNA-binding domain are required
for the interaction between p53 and proteins from the Bcl-2 family
[85,86], yet their mutation/absence fails to modify the p53 autop-
hagy-inhibitory potential [84]. Thus, the molecular features that
account for autophagy suppression by p53 remain to be discovered. It
is also elusive whether this effect relies on the direct interaction
between p53 and hitherto unidentiﬁed factors or rather is the result of
more indirect metabolic circuitries.
Not surprisingly, p53 inhibition (as well as many other pro-
autophagic triggers) has been reported to promote autophagy only in
the G1 and early S phases of the cell cycle [87,88]. It would have
appeared paradoxical, indeed, that p53-deﬁcient cells (which are
characterized by a growth rate similar to that of theirWTcounterparts)
continuously upregulate autophagy throughout the cell cycle (includ-
ing the late S and G2/M phases), because a simultaneous increase in
catabolism and anabolism would dramatically augment bioenergetic
needs of the cells, thereby limiting their rate of proliferation [87].
While p53-dependent transcriptional programs may stimulate
autophagy, several lines of evidence indicate that cytoplasmic (but not
nuclear) p53 inhibits the autophagic pathway. Short deletions and
single amino acids substitutions in p53 are found in more than 50% of
human tumors. Mutant p53 proteins constitute a multifaceted family
of several hundredmembers with heterogeneous properties [89]. Still,
most of the oncogenic mutations of p53 map to its DNA-binding
domain [90], which is required for the activity of p53 as a transcription
factor and for its interactionwith Bcl-2 [85], but not for its autophagy-
suppressing functions [69,84]. In this scenario, it is tempting to
speculate that some (but probably not all) cancer-associated muta-
tionsmay “hit” p53 activity in a double (or even triple) fashion. At least
theoretically, such mutations may indeed promote tumorigenesis by
inactivating the mitochondrial (pro-apoptotic) and nuclear (pro-
apoptotic, cell cycle-arresting and pro-autophagic) functions of p53,
while leaving unaffected (or even potentiating) p53-mediated
suppression of autophagy [84]. Conclusive experimental data to
conﬁrm/disconﬁrm this hypothesis are urgently awaited.
4. Cytoprotective roles of autophagy during anticancer therapy
Numerous conventional and experimental antitumor strategies are
able to induce amassive accumulation of autophagosomes, both in vitro
(in cancer cell lines) [7] and in vivo (in tumors xenografted to
immunodeﬁcient mice) [76,91,92]. Frequently, such an extensive
vacuolization of the cytoplasm has been considered as (one of) the
most prominent manifestation(s) of the so-called “autophagic cell
death” [8,93]. According to this perspective, which nowadays is rather
discredited [9,10], autophagywould represent an additionalmechanism
of cell death, and its inhibition would afford cytoprotective effects. On
the contrary, while the inhibition of autophagy often shifts the cell
death morphotype to a non-autophagic one, it rarely prevents the
radio- and chemotherapy-induced demise of cancer cells, and often
accelerates it [7,8].
Thus, both pharmacological inhibitors of autophagy (e.g., 3-
methyladenine, hydroxychloroquine, baﬁlomycin A1, monensin) and
siRNAs that target essential modulators of the autophagic machinery
(e.g., Atg3, Atg4b, Atg4c, Bec-1/Atg6, Atg10 and Atg12) have been
shown to sensitize cancer cells to awide spectrum of stress conditions,
including (but not limited to): glucose and amino acid deprivation
[70,94]; growth factor withdrawal [12]; detachment from the extra-
cellular matrix (i.e., anoikis) [95,96]; estrogen receptor antagonism
with tamoxifen [97]; androgendeprivation [98]; radiation therapy [99];
DNA alkylation damage with cyclophosphamide [76] or temozolomide
[100]; inhibition of TKRs with imatinib [101]; inhibition of cyclooxy-
genases with sulindac sulﬁde [102]; as well as N-(4-hydroxyphenyl)
retinamide- [103], anthocyanin- [104] and TRAIL-induced cell death
1529E. Morselli et al. / Biochimica et Biophysica Acta 1793 (2009) 1524–1532[105] (Table 2). Similarly, in a murine model of Myc-induced
lymphoma, inhibition of autophagy with either chloroquine or Atg5-
targeted short hairpin RNAs (shRNAs) facilitated tumor regressionTable 2
Examples of autophagy inhibition as a tumor cell sensitizing strategy.
Cell type⁎ Autophagy inhibition
Breast adenocarcinoma cells siRNA-mediated downregulation
MCF7 MCF7HER2 Atg5 Atg7
T47D Bec-1
Cervical cancer cells Pharmacological inhibitors
HeLa 3-MA Baf-A1
HCQ Monensin
siRNA-mediated downregulation
Atg5 Atg10
Atg12 Bec-1
Colorectal cancer cells Pharmacological inhibitors
HT-29 3-MA
Colorectal cancer cells Pharmacological inhibitors
bax−/− HCT-116 3-MA E64D
HCT-116-FLIP PepA
WT HCT-116 siRNA-mediated downregulation
Bec-1 UVRAG
Colorectal cancer cell lines Pharmacological inhibitors
DLD-1 LoVo 3-MA E64D
SW480 SW620 PepA
WiDr Atg7-targeted siRNA
Glioma cell lines Pharmacological inhibitors
U87-MG U373-MG 3-MA Baf-A1
Glioma cell lines Pharmacological inhibitors
LN229 LZN308 3-MA Baf-A1
U87-MG U373-MG RTA 203
Atg5-targeted siRNA
Glioma cell lines Pharmacological inhibitors
A172 T98G 3-MA Baf-A1
U87-MG U373-MG
HCC cells Pharmacological inhibitors
PLC/PRF/5 HepG2 3-MA
Rat HCC cells Atg5-targeted siRNA
McArdle
Prostate cancer cells Pharmacological inhibitors
LNCaP 3-MA
Bec-1-targeted siRNA
Murine primary cells Pharmacological inhibitors
bax−/− bak−/− bone marrow cells 3-MA CQ
siRNA-mediated downregulation
Atg5 Atg7
Murine primary cells Pharmacological inhibitors
Myc/p53ERTAM bone marrow cells CQ
Atg7-targeted shRNA
Primary MECs siRNA-mediated downregulation
1°HMECs MCF10A Atg5 Atg7
Canine kidney cell line
MDCK-2
Murine ﬁbroblasts
atg5−/− MEFs WT MEFs
Various tumor cell lines siRNA-mediated downregulation
A549 HTB35 Atg3 Atg4b
HTB43 MDA-MB231 Atg4c Atg10
Sw707 Atg12
⁎ Unless otherwise indicated, cells were of human origin. Abbreviations: 3-MA, 3-met
baﬁlomycin A1; Bec-1, beclin-1; CQ, chloroquine, HCC, hepatocellular carcinoma; HCQ, hydr
mammary epithelial cells; MEFs, mouse embryonic ﬁbroblasts; PepA, pepstatin A; shRNA, s
temozolomide; TRAIL, tumor necrosis factor-related apoptosis inducing ligand; WT, wild tyinduced by p53 reactivation and DNA damage [76]. Altogether, these
examples substantiate the idea that autophagy is activated by tumor
cells as a pro-survival mechanism against cytotoxic agents and mayStress condition Ref.
Estrogen receptor antagonism with tamoxifen [97]
Nutrient depletion [70]
Cyclooxygenase inhibition with sulindac sulﬁde [102]
TRAIL-induced cell death [105]
Amino acid and glucose deprivation [94]
4-HPR-induced cell death [103]
Inhibition of TKRs with imatinib [101]
TMZ-induced cell death [100]
Anthocyanin-induced cell death [104]
Androgen deprivation [98]
Interleukin-3 withdrawal [12]
DNA alkylation damage with cyclophosphamide [76]
ECM detachment (anoikis) Starvation [95]
γ-irradiation [99]
hyladenine; 4-HPR, N-(4-hydroxyphenyl)retinamide; Atg, autophagy related; Baf-A1,
oxychloroquine; ECM, extracellular matrix; MDCK, Madin–Darby canine kidney; MECs,
hort hairpin RNA: siRNA, small interfering RNA; TKRs, tyrosine kinase receptors; TMZ,
pe.
Fig. 3. Pro-survival roles of autophagy. Upon hypoxic, metabolic, detachment-induced
and therapeutic stress, tumor cells activate a general pro-survival response centered on
autophagy. In multiple experimental settings, pharmacological and/or genetic inhibi-
tion of autophagy has been shown to sensitize cancer cells to the lethal effect of different
types of stress. Thus, suppression of the autophagic pathway may represent a valuable
therapeutic strategy for radio- and chemosensitization.
1530 E. Morselli et al. / Biochimica et Biophysica Acta 1793 (2009) 1524–1532therefore favor radio- and chemoresistance (Fig. 3). Thus, suppression
of the autophagic ﬂow may represent a general strategy to sensitize
cancer cells to radio- and chemotherapy-induced cell death. Upon
surgical resection, the combination of chloroquine (a lysosomotropic
amine that has been widely employed against malaria) with conven-
tional antitumor therapies has shown encouraging results for the
therapy of glioblastomamultiforme [106]. Only futurewill tell whether
autophagy inhibition will become a widespread clinical approach for
radio- and chemosensitization of tumors.
5. Concluding remarks
Autophagy occupies the center of a complex network of cellular
responses to stress. For this reason, the relationship between
autophagy and cancer cannot be recapitulated by a simple and
uniform principle [107]. As we have discussed here, on one hand
autophagy may exert tumor suppressing functions by: (1) limiting
chromosomal instability and therefore preventing the accumulation
of oncogenic mutations; (2) restricting oxidative stress, which is also
an oncogenic stimulus; and (3) reducing intratumoral necrosis and
local inﬂammation. Thus, disabled autophagy might constitute a
common feature of cancer that adds to the hallmarks originally
formulated in 2000 by Hanahan and Weinberg [108] and more
recently integrated by other authors [109,110], namely provision of
autonomous growth stimuli, insensitivity to antiproliferative signals,
disabled apoptosis, limitless replication, production of angiogenic
factors, tissue invasion with metastasis [108], avoidance of the
immune response [110], and enhanced anabolic metabolism [109].
On the other hand, enhanced autophagy likewise represents a
prominent mechanism used by tumor cells to escape hypoxic,
metabolic, detachment-induced and therapeutic stress. Moreover,
p53, which has a crucial role in suppressing tumorigenesis, regulates
autophagy in an apparently paradoxical fashion, depending on its
subcellular localization. The pharmacological modulation of autophagy
might therefore represent a valuable tool for anticancer therapy.
Autophagy induction might be employed for tumor chemoprevention.
Conversely, suppression of the autophagic pathway may be combined
with conventional or experimental antitumor regimens to achieve
increased efﬁcacy, thereby allowing for lower dosage and limited side
effects. Still, autophagy inhibition might have an intrinsic oncogenic
potential and it may be applicable only in selected clinical settings. As itstands, only some of the links between autophagy and cancer have been
elucidated. Results of future studies are urgently awaited to shed
additional light on this therapeutically promising relationship.
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